New pricing models could improve access to innovative cancer drugs

A consensus panel, representing 16 leading academic institutions, charities, stakeholder groups and pharmaceutical companies, has concluded that the NHS could improve patient access to new cancer drugs by varying drug prices depending on the particular indication of a treatment.

SPS commentary:

The panel also backed outcome-based pricing, where the NHS only pays the full agreed price for a drug when it delivers the anticipated benefits.

PharmaTimes